Enanta Pharmaceuticals (ENTA) News Today $6.28 +0.42 (+7.17%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy BuchananDecember 14, 2024 | markets.businessinsider.comFY2025 Earnings Forecast for ENTA Issued By Leerink PartnrsDecember 14, 2024 | americanbankingnews.comEvercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)December 12, 2024 | markets.businessinsider.comEquities Analysts Set Expectations for ENTA FY2025 EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Enanta Pharmaceuticals in a research note issued on Monday, December 9th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology companDecember 12, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA) Gets a Hold from OppenheimerDecember 11, 2024 | markets.businessinsider.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Tara Lynn Kieffer Sells 2,283 SharesDecember 11, 2024 | insidertrades.comPoint72 Asset Management L.P. Acquires Shares of 87,190 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Point72 Asset Management L.P. bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 87,190 shares of the biotechnology company's stock,December 11, 2024 | marketbeat.comEnanta Reports Positive Phase 2 Data For Zelicapavir In Paediatric RSV Study; Stock UpDecember 9, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)December 9, 2024 | businesswire.comEnanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)December 6, 2024 | businesswire.comErste Asset Management GmbH Buys Shares of 120,000 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Erste Asset Management GmbH purchased a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 120,000 shares of the bioteDecember 4, 2024 | marketbeat.comCaligan Partners LP Cuts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Caligan Partners LP decreased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 69.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 322,453 shares of the bioteDecember 1, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recoDecember 1, 2024 | marketbeat.comEnanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlookNovember 30, 2024 | investing.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024November 27, 2024 | businesswire.comEnanta price target lowered to $20 from $26 at BairdNovember 26, 2024 | markets.businessinsider.com4 Analysts Assess Enanta Pharma: What You Need To KnowNovember 26, 2024 | benzinga.comEnanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday.November 26, 2024 | marketbeat.comEnanta Pharma Earnings Analysis: Q4 RecapNovember 26, 2024 | benzinga.comEnanta Pharma Q4 Earnings AssessmentNovember 26, 2024 | benzinga.comEnanta Pharmaceuticals: Promising RSV Developments and Strong Immunology Pipeline Justify Buy RatingNovember 26, 2024 | markets.businessinsider.comEnanta Pharma Q4 2024 Earnings PreviewNovember 24, 2024 | msn.comEnanta Pharma's Earnings OutlookNovember 22, 2024 | benzinga.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200-Day Moving Average - Should You Sell?Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Passes Below 200 Day Moving Average - Here's WhyNovember 14, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one haNovember 6, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 282,755 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. cut its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 66.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,806 shares of the biotechnology company'sNovember 2, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Large Growth in Short InterestEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,430,000 shares, an increase of 14.7% from the September 30th total of 2,990,000 shares. Approximately 17.4% of the company's stock are sold short. Based on an average trading volume of 165,700 shares, the short-interest ratio is currently 20.7 days.October 29, 2024 | marketbeat.comThe past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitableOctober 27, 2024 | finance.yahoo.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average - Here's What HappenedEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?October 22, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust PipelineOctober 19, 2024 | finance.yahoo.comMillennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals SharesOctober 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Position Lowered by AQR Capital Management LLCAQR Capital Management LLC trimmed its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 45.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 60,005 shares of the biotechnology company's stock afterOctober 14, 2024 | marketbeat.comDimensional Fund Advisors LP Trims Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Dimensional Fund Advisors LP decreased its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 31.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,062 shares of the biotechnologyOctober 12, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issuOctober 12, 2024 | marketbeat.comBuy Rating Affirmed for Enanta Pharmaceuticals on Strong Clinical Trial Outcomes and Promising Pipeline ValuationOctober 10, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday.October 10, 2024 | marketbeat.comBuy Rating for Enanta Pharmaceuticals Amid Reduced Competition and Promising Drug TrialsOctober 9, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Enanta Pharma Through 4 AnalystsOctober 9, 2024 | benzinga.comEnanta Pharmaceuticals Gains Buy Rating on Strong Clinical Results for EDP-323September 28, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In StudySeptember 27, 2024 | benzinga.comEnanta Pharmaceuticals (ENTA) Gets a Hold from Leerink PartnersSeptember 27, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)September 26, 2024 | businesswire.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Armistice Capital LLCArmistice Capital LLC lowered its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 11.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,096,000 shareSeptember 26, 2024 | marketbeat.comArdelyx, Inc. (41X.F)September 23, 2024 | sg.finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Up 5.7% in AugustEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 2,960,000 shares, a growth of 5.7% from the July 31st total of 2,800,000 shares. Currently, 15.0% of the shares of the company are short sold. Based on an average daily volume of 184,800 shares, the days-to-cover ratio is currently 16.0 days.September 3, 2024 | marketbeat.comEnanta Pharmaceuticals Inc.August 27, 2024 | barrons.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, twoAugust 23, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 157,097 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. reduced its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 26.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 426,561 shares of the biotechnologyAugust 19, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)August 11, 2024 | markets.businessinsider.comEnanta Pharmaceuticals, Inc. (ENTA): Caligan Partners' Top Holding Right Now?August 9, 2024 | msn.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address This Indicator called BOTH NVDA rallies (Ad)Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼0.330.60▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼12▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRTC News Today HUMA News Today ANAB News Today CRMD News Today MREO News Today XERS News Today ABVX News Today MGTX News Today RNAC News Today GLUE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTA Stock Alerts